Quoin Pharmaceuticals Ltd. Research and Development Expense
Quoin Pharmaceuticals Ltd. (QNRX) reported Research and Development Expense of $3.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Quoin Pharmaceuticals Ltd. research and development expense for the quarter ending 2026-06-30 was $3.63M, a 76.88% increase year-over-year.
- Quoin Pharmaceuticals Ltd. research and development expense for the quarter ending 2026-03-31 was $3.43M, a 44.63% increase year-over-year.
- Quoin Pharmaceuticals Ltd. research and development expense for the quarter ending 2025-12-31 was $3.10M, a 194.88% increase year-over-year.
- Quoin Pharmaceuticals Ltd. research and development expense for the quarter ending 2025-09-30 was $2.28M, a 111.29% increase year-over-year.
- Quoin Pharmaceuticals Ltd. research and development expense for fiscal 2025 was $9.80M, a 172.10% increase from fiscal 2024.
- Quoin Pharmaceuticals Ltd. research and development expense for fiscal 2024 was $3.60M, a 8.91% increase from fiscal 2023.
- Quoin Pharmaceuticals Ltd. research and development expense for fiscal 2023 was $3.31M, a 23.76% increase from fiscal 2022.
- Quoin Pharmaceuticals Ltd. research and development expense for fiscal 2022 was $2.67M, a 71.01% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.63M 10-Q · filed 2026-08-14 | $7.06M 10-Q · filed 2026-08-14 | $10.16M derived: sum of 3 quarters · filed 2026-08-14 | $12.44M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $3.43M 10-Q · filed 2026-05-07 | $6.53M derived: sum of 2 quarters · filed 2026-05-07 | $8.81M derived: sum of 3 quarters · filed 2026-05-07 | $10.86M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $5.38M derived: sum of 2 quarters · filed 2026-03-26 | $7.43M derived: sum of 3 quarters · filed 2026-08-14 | $9.80M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $2.28M 10-Q · filed 2025-11-06 | $4.33M derived: sum of 2 quarters · filed 2026-08-14 | $6.71M 10-Q · filed 2025-11-06 | $7.76M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $2.05M 10-Q · filed 2026-08-14 | $4.42M 10-Q · filed 2026-08-14 | $5.47M derived: sum of 3 quarters · filed 2026-08-14 | $6.55M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $2.37M 10-Q · filed 2026-05-07 | $3.42M derived: sum of 2 quarters · filed 2026-05-07 | $4.50M derived: sum of 3 quarters · filed 2026-05-07 | $5.09M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.13M derived: sum of 2 quarters · filed 2026-03-26 | $2.72M derived: sum of 3 quarters · filed 2026-03-26 | $3.60M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $1.08M 10-Q · filed 2025-11-06 | $1.17M 10-Q · filed 2024-11-08 | $1.67M derived: sum of 2 quarters · filed 2025-11-06 | $2.55M 10-Q · filed 2025-11-06 | $2.53M 10-Q · filed 2024-11-08 | $3.38M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $587.50K 10-Q · filed 2025-08-07 | $519.35K 10-Q · filed 2024-08-08 | $1.47M 10-Q · filed 2025-08-07 | $1.36M 10-Q · filed 2024-08-08 | $2.31M derived: sum of 3 quarters · filed 2025-08-07 | $3.06M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $885.30K 10-Q · filed 2025-05-13 | $842.83K 10-Q · filed 2024-05-09 | $1.72M derived: sum of 2 quarters · filed 2025-05-13 | $2.48M derived: sum of 3 quarters · filed 2025-05-13 | $3.10M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $832.39K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.59M derived: sum of 2 quarters · filed 2025-03-13 | $2.22M derived: sum of 3 quarters · filed 2025-03-13 | $3.31M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $758.76K 10-Q · filed 2024-11-08 | $1.38M derived: sum of 2 quarters · filed 2024-11-08 | $2.48M 10-Q · filed 2024-11-08 | $3.09M derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2023-06-30 | $625.10K 10-Q · filed 2024-08-08 | $1.72M 10-Q · filed 2024-08-08 | $2.33M derived: sum of 3 quarters · filed 2024-08-08 | $3.08M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $1.09M 10-Q · filed 2024-05-09 | $1.70M derived: sum of 2 quarters · filed 2024-05-09 | $2.45M derived: sum of 3 quarters · filed 2024-05-09 | $3.18M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $613.07K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.36M derived: sum of 2 quarters · filed 2024-03-14 | $2.09M derived: sum of 3 quarters · filed 2024-03-14 | $2.67M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $745.51K 10-Q · filed 2023-11-09 | $1.47M derived: sum of 2 quarters · filed 2023-11-09 | $2.06M 10-Q · filed 2023-11-09 | $3.07M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $726.69K 10-Q · filed 2023-08-03 | $1.31M 10-Q · filed 2023-08-03 | $2.32M derived: sum of 3 quarters · filed 2023-08-03 | $2.58M derived: sum of 4 quarters · filed 2023-08-03 | |||
| 2022-03-31 | $587.57K 10-Q · filed 2023-05-09 | $1.59M derived: sum of 2 quarters · filed 2023-05-09 | $1.85M derived: sum of 3 quarters · filed 2023-05-09 | $2.09M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $1.01M derived: 10-K 12 month − 6-K 9 month · filed 2023-03-15 | $1.27M derived: sum of 2 quarters · filed 2023-03-15 | $1.51M derived: sum of 3 quarters · filed 2023-03-15 | $1.56M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $260.00K 6-K · filed 2022-11-10 | $499.28K derived: sum of 2 quarters · filed 2022-11-10 | $556.06K 6-K · filed 2022-11-10 | ||||
| 2021-06-30 | $239.28K 6-K · filed 2022-08-18 | $296.07K 6-K · filed 2022-08-18 | |||||
| 2020-12-31 | $244.16K 20-F · filed 2022-04-14 | ||||||
| 2019-12-31 | $45.65K 20-F · filed 2022-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |